Fresh analysis reveals that individuals who discontinue new GLP-1 drugs like semaglutide or tirzepatide may regain shed pounds much more quickly than those who stop conventional lifestyle programs.
Published data in a prominent health publication points out that while obese people can lose about a fifth of their body weight while undergoing treatment, the weight comes back at an average rate of nearly a kilo each month once they quit.
"People purchasing such medications must be cognizant of the danger of fast weight regain when the medication ends," warns researcher Dr. Susan Jebb.
This pace of regain implies a reversion to starting mass within about 18 months.
Weighing Treatments
The study, which examined 37 of trials involving thousands of patients, compared the results of the injectable medications with older methods.
Researchers point out that people who shed pounds through lifestyle changes alone usually see a more gradual creep back—approximately 0.1 kg a month—once they finish.
Explaining the Rapid Regain
Experts propose the mode of action of the jabs is key to understanding the heightened rebound.
GLP-1 drugs copy a natural hormone called GLP-1, which controls hunger.
"Artificially providing GLP-1 concentrations far above than the body's typical production may cause the body to generate a reduced amount of its own natural GLP-1, and could diminish responsiveness to its effects," said Dr. Adam Collins, a nutrition researcher.
"Stopping of this hormone supplement means hunger is unsuppressed, making binge eating a significant risk."
An Ongoing Issue?
The NHS advise the injections for people with obesity-related health risks, accompanied by recommended lifestyle changes.
Professionals contend that, due to the high risk of weight regain, the treatment should be considered ongoing.
This opinion is supported by drug manufacturers, who note that the findings "emphasize the persistent character of excess weight," comparing it to managing diseases like diabetes.
Patient Experiences
People who have discontinued the jabs describe a powerful return of appetite.
"I experienced a trigger flipping and you become ravenous," said a patient.
This challenge is compounded if patients have not developed permanent lifestyle or habit changes during therapy.
Widespread Interest
Figures show that a significant number of people in the UK have tried weight-loss jabs in the last 12 months, with demand continuing to grow.
- Use is more common among females compared to men.
- The 40s and 50s age group shows the greatest level of interest.
- A large proportion access the medications through private prescriptions rather than the NHS.
Ultimately, researchers stress that while the jabs are powerful tools for weight loss, they are not a standalone cure and long-term success relies on combined lifestyle management.
